← Leaderboards
Mitchell Goldman
Indiana Univ-Purdue Univ At Indianapolis
$10,867,864
Attributed
$10,867,864
Total exposure
15
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–08$2M$1.5M$1M$500K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$10,867,864 · 15
By mechanism
U01$10,600,988 · 1
R01$266,876 · 1
M01$0 · 13
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Kenneth H. Fife$1,137,888
- Joseph Wheat$0
- Martin Bard$1,611,735
- Md Michael Frank$0
- Esperanza A Martinez-Mier$781,444
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationAids TherapyClinical ResearchCombination ChemotherapyHiv InfectionsClinical Trial Phase IChemopreventionOpportunistic InfectionsMycobacterium AviumDrug Screening /EvaluationAntiaids AgentAidsMicroorganism Disease ChemotherapyCd4 MoleculeDelavirdineMycobacterium IntracellulareProtease InhibitorPneumocystis PneumoniaHuman Immunodeficiency Virus 1PharmacokineticsLamivudineZidovudine2'3'Dideoxyinosine
Grant awards (99)
ADULT AIDS CLINICAL TRIALS UNIT$452,645
U01 · FY2008 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,030,283
U01 · FY2007 · AI · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,386,661
U01 · FY2006 · AI · contact PI
Endothelial Dysfunction Due to HIV-1 Protease Inhibitors$266,876
R01 · FY2006 · HL · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,881,400
U01 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$1,790,506
U01 · FY2004 · AI
ADULT AIDS CLINICAL TRIALS UNIT$2,028,458
U01 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT$2,031,035
U01 · FY2002 · AI
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2002 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2002 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2002 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2002 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2002 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2002 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2002 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2002 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2002 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2002 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2002 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2002 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2001 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2001 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2001 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2001 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2001 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2001 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2001 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2001 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2001 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2001 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2001 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2001 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2000 · RR
DISCONTINUING THERAPY IN SUBJECTS W/ DISSEMINATED MAC$0
M01 · FY2000 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2000 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2000 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2000 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2000 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2000 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2000 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE PLUS NELFINAVIR, DIDANOSINE, STAVUDINE FOR HIV 1$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2000 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2000 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2000 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2000 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2$0
M01 · FY2000 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2000 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2000 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2000 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2000 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2000 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2000 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2000 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2000 · RR
TIPRANAVIR/RITONAVIR COMB W/ REVERSE TRANSCRIPTASE INHIB$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN HIV INFECTION$0
M01 · FY2000 · RR
FOUR DRUG ANTIRETROVIRAL REGIMEN ALONE OR COMB IN HIV$0
M01 · FY2000 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
ABT378/RITONAVIR IN COMBINATION WITH NEVIRAPINE IN HIV$0
M01 · FY2000 · RR
PHASE IV RANDOMIZED STUDY OF FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY$0
M01 · FY2000 · RR
ANTIFUNGAL THERAPY FOR HISTOPLASMOSIS$0
M01 · FY2000 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2000 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2000 · RR
ACTG 341: PATHOGENESIS OF MAC DISEASE IN ADVANCED HIV 1 &HAART IMPAC$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2000 · RR
DELAVIRDINE MESYLATE FOR HIV 1+NEWLY ENROLLED PTS ALSO IN M/3331/0021$0
M01 · FY2000 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG888: DISCONTINUING PCP PROPHYLAXIS IN PTS W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR